Quick Answer
Kymera Therapeutics, Inc. reported Operating Income Loss of -$349.40 million for the year ending 2025.
- Kymera Therapeutics, Inc. showed a decrease of -33.5% in Operating Income Loss from 2024 to 2025.
- This data is from Kymera Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: -$11.86 million | Q1 2020: -$11.25 million | Q2 2020: -$14.19 million | Q3 2020: -$8.08 million | Q1 2021: -$13.17 million | Q2 2021: -$24.73 million | Q3 2021: -$28.64 million | Q1 2022: -$36.93 million | Q2 2022: -$40.81 million | Q3 2022: -$44.88 million | Q1 2023: -$45.33 million | Q2 2023: -$43.38 million | Q3 2023: -$57.51 million | Q1 2024: -$57.83 million | Q2 2024: -$50.93 million | Q3 2024: -$72.12 million | Q1 2025: -$74.43 million | Q2 2025: -$84.56 million | Q3 2025: -$92.52 million.
- Over the full 7 years of available data (2019 to 2025), Kymera Therapeutics, Inc.'s Operating Income Loss has declined by 727.9%.
- Historical annual values: Fiscal year 2025: -$349.40 million | Fiscal year 2024: -$261.64 million | Fiscal year 2023: -$165.53 million | Fiscal year 2022: -$161.26 million | Fiscal year 2021: -$100.53 million | Fiscal year 2020: -$46.30 million | Fiscal year 2019: -$42.21 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: